Miyashita et al.44 have also demonstrated that high CD8+ TIL levels and CD8/FOXP3 ratios in residual tumors accurately predict better clinical outcomes in patients with TNBC with non-pCR after NAC, and that the changes in these parameters in BC tissues after NAC are significantly associated with eventual clinical outcomes in TNBCs. The gene discussed is FOXP3; the disease is breast cancer.